Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer × fluzoparib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Sarcoma, Ewing 1 SCLC, Extensive Stage 1 Fludzoparib" and Anti-angiogenic 1 Breast Neoplasms 1 Advanced Solid Tumors 1 Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Sun Yat-sen University

Phase 2 Suspended

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡